BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Varyani F, Argyriou K, Phillips F, Tsakiridou E, Moran GW. Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data. Drug Des Devel Ther 2019;13:4091-105. [PMID: 31819376 DOI: 10.2147/DDDT.S182891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Magro F, Estevinho MM. Is tofacitinib a game-changing drug for ulcerative colitis? United European Gastroenterol J 2020;8:755-63. [PMID: 32552501 DOI: 10.1177/2050640620935732] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
2 Dhillon P, Singh K. Therapeutic applications of probiotics in ulcerative colitis: An updated review. PharmaNutrition 2020;13:100194. [DOI: 10.1016/j.phanu.2020.100194] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
3 Brand RM, Moore BA, Zyhowski A, Siegel A, Uttam S, Metter EJ, Engstrom J, Brand RE, Biswas N, Whitcomb DC, Binion DG, Schwartz M, McGowan I. Tofacitinib inhibits inflammatory cytokines from ulcerative colitis and healthy mucosal explants and is associated with pSTAT1/3 reduction in T-cells. Am J Physiol Gastrointest Liver Physiol 2021;320:G396-410. [PMID: 33355506 DOI: 10.1152/ajpgi.00383.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Dig Liver Dis 2021;53:803-8. [PMID: 33744172 DOI: 10.1016/j.dld.2021.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Shrestha GS, Bista B, Dhungana A, Poudel N, Bhattarai S, Shrestha M, Bhandari S, Vaidya B. Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report. JNMA J Nepal Med Assoc 2021;59:593-6. [PMID: 34508399 DOI: 10.31729/jnma.6680] [Reference Citation Analysis]